BM
Bristol-Myers Squibb Company PFD CONV 2
BMYMP · OTC
$400.00 -57.46% (-$540.22)
Market Cap $814.6B
P/E Ratio 115.94x
Div. Yield 0.38%
ROE 25.85%
Bulios Fair Price
$555.44
38.9% upside
Current Price
$400
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BMYMP is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
0 /100
Expensive P/E 115.94x
P/FCF 53.23x
EV/EBITDA 54.94x
Growth
79 /100
Growing EPS growth 13.64%
Book val. growth 15.56%
Rev. growth 20.86%
Profitability
97 /100
Strong Gross margin 63.15%
FCF margin 31.75%
Net margin 14.64%
Quality
100 /100
Excellent ROIC 90.34%
Asset turnover 4.52x
ROE 25.85%
Debt
47 /100
Moderate Debt/Equity -0.81x
Net debt/EBITDA -4.00x
Current ratio -4.72x
Stability
11 /100
Unstable Beta 0.27x
Profitable years 0
Rev. volatility 34.01%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BMYMP
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher S. Boerner
Employees
34,100
Headquarters
Princeton